Biocept, Inc. (BIOC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.4200 |
| Open | 1.4000 |
| Bid | 1.4500 x 1800 |
| Ask | 1.5100 x 4000 |
| Day's Range | 1.4000 - 1.4900 |
| 52 Week Range | 1.4000 - 4.9700 |
| Volume | |
| Avg. Volume | 113,209 |
| Market Cap | 25.095M |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | 6.80 |
| EPS (TTM) | 0.2190 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.50 |
- Business Wire
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
SAN DIEGO, May 16, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022. The delay is related to the ongoing accounting review of Biocept’s financial statements as of and for the three months ended March 31, 2022, which ongoing review is a result of a change in circumstances at the U.S. Health Resources Services Administration (HR
- Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 08, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 519,140 shares of its common stock to 44 new employees, including an inducement stock option to purchase 150,000 shares of its common stock to Philippe Marchand, Ph.D., its new Chief Operations Officer. The inducement stock options have a grant date of March 31, 2022, and were gr
- Business Wire
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
SAN DIEGO, April 06, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2021 and provides a business update.
